company background image
QGEN logo

Qiagen NYSE:QGEN Stock Report

Last Price

US$42.79

Market Cap

US$9.6b

7D

-1.7%

1Y

-9.4%

Updated

29 Feb, 2024

Data

Company Financials +

QGEN Stock Overview

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.

QGEN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Qiagen N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Qiagen
Historical stock prices
Current Share PriceUS$42.79
52 Week HighUS$49.18
52 Week LowUS$35.81
Beta0.43
1 Month Change-1.72%
3 Month Change0.14%
1 Year Change-9.37%
3 Year Change-12.77%
5 Year Change6.65%
Change since IPO2,014.06%

Recent News & Updates

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Recent updates

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio

Jul 15

Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Jun 29
Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

May 26
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) A Risky Investment?

Apr 29
Is Qiagen (NYSE:QGEN) A Risky Investment?

Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?

Mar 30
Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?

Shareholder Returns

QGENUS Life SciencesUS Market
7D-1.7%1.4%0.4%
1Y-9.4%1.8%24.9%

Return vs Industry: QGEN underperformed the US Life Sciences industry which returned 4.7% over the past year.

Return vs Market: QGEN underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is QGEN's price volatile compared to industry and market?
QGEN volatility
QGEN Average Weekly Movement3.3%
Life Sciences Industry Average Movement7.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: QGEN has not had significant price volatility in the past 3 months.

Volatility Over Time: QGEN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19866,000Thierry Bernardhttps://www.qiagen.com

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

Qiagen N.V. Fundamentals Summary

How do Qiagen's earnings and revenue compare to its market cap?
QGEN fundamental statistics
Market capUS$9.56b
Earnings (TTM)US$341.30m
Revenue (TTM)US$1.97b

27.8x

P/E Ratio

4.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QGEN income statement (TTM)
RevenueUS$1.97b
Cost of RevenueUS$659.03m
Gross ProfitUS$1.31b
Other ExpensesUS$964.98m
EarningsUS$341.30m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.54
Gross Margin66.47%
Net Profit Margin17.37%
Debt/Equity Ratio39.7%

How did QGEN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.